NCT05013905CompletedPhase 2
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety and efficacy of tulisokibart (MK-7240) in participants with moderately to severely active Crohn's Disease. After the completion of the 12-week Induction Period, eligible participants have the option to enter an Open-label Extension (OLE) Period for up to 170 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- First submitted
- 13 Aug 2021
- Start date
- 28 Jul 2021
- Primary completion date
- 23 Sept 2022
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Diseases
- Crohn's disease
- NCT number
- NCT05013905
- EU CT number
- 2023-509742-35-00
- EudraCT number
- 2021-000092-37
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 55
- From 28 Jul 2021 to the primary completion date, 23 Sept 2022
- 26 sites in 8 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Women of child bearing potential (WOCBP) and men with female partner of childbearing potential who are unwilling to use two highly effective methods of contraception to avoid pregnancy for the entire study period and up to 12 weeks after the last dose of study drug
- Previous small bowel resection with a combined resected length of \>100 cm or previous colonic resection of \> 2 segments
- Surgical bowel resection within 3 months before screening
Lab values
- Participants who meet the protocol criteria for important laboratory exclusion criteria
Other
- Diagnosis of ulcerative colitis (UC) or indeterminate colitis
- CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or illeal involvement
- Suspected or diagnosed intra-abdominal or perianal abscess at screening
- Current stoma or need for colostomy or ileostomy
- Past or current evidence of definite low-grade or high-grade colonic dysplasia not completely removed
- Participants in the opinion of the investigator are at an unacceptable risk for participation in the study
Who the study is looking for
- Confirmed diagnosis of Crohn's disease (CD)
- Moderately to severely active CD as defined by Crohn's disease activity index (CDAI) score and centrally read endoscopy
- Must have corticosteroid dependence or have had no response, insufficient response, loss of response and/or intolerance to at least one of the following therapies: corticosteroid, immunosuppressants, or an approved anti-tumor necrosis factor (TNF), anti-integrin, or anti-interleukin (IL)12/23
- Able to provide written informed consent and understand and comply with the requirements of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (26)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.